
Death row inmate whose execution was postponed found dead in cell
pharmafile | January 9, 2019 | News story | Research and Development | Alvogen, Scott Dozier, execution, pharma, prison
Scott Dozier, the death row inmate whose execution was stalled by court cases launched by pharmaceutical companies, has been found dead in his cell.
The 48 year old, an inmate on Nevada’s death row, had in July of last year had his execution postponed twice after a Nevada judge temporarily halted the use of the sedative midazolam in executions, following objections from the New Jersey based pharma firm Alvogen.
The case, in which Alvogen claimed that the Nevada Department of Corrections obtained the drug illegaly, saw Dozier’s executions halted just 11 hours before he was scheduled to die.
Speaking to the Associated Press, State Department of Corrections spokeswoman Brooke Santina reported that Dozier had been found dead at 4:35 p.m. on Saturday in his solo cell. The twice convicted killer was reported to have died from an apparent hanging.
Dozier had repeatedly asked to be executed and given up on appeals as he suggested that he would rather die than spend the rest of his life in prison.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






